10-Q: Quantum-Si Reports Q2 Loss Amid Revenue Dip, Secures $50M Funding

Quantum-Si Incorporated reported an increased net loss for the six months ended June 30, 2025, despite a year-over-year revenue increase, while securing significant capital through recent equity offerings.

Summary

• Net loss for the six months ended June 30, 2025, increased to $48.0 million from $42.6 million in the prior year period.
• Total revenue for the six months ended June 30, 2025, grew by 32.8% to $1.43 million, compared to $1.08 million in the same period of 2024.
• However, revenue for the three months ended June 30, 2025, decreased by 5.0% to $0.59 million, compared to $0.62 million in the same period of 2024, primarily due to longer capital sales cycles driven by NIH budget cuts.
• Gross profit margin improved slightly to 58.4% for the six months ended June 30, 2025, from 57.7% in the prior year.
• Research and development expenses increased by 9.2% to $28.9 million for the six months, driven by fabrication and outsourced services for the Proteus platform.
• Selling, general and administrative expenses decreased slightly by 0.7% to $23.8 million for the six months.
• Net cash used in operating activities increased to $46.4 million for the six months ended June 30, 2025, from $41.8 million in the prior year.
• The company completed a January 2025 Registered Direct Offering, raising approximately $46.8 million in net proceeds.
• A subsequent July 2025 Registered Direct Offering raised an additional $46.9 million in net proceeds.
• A preliminary settlement was reached in the Delaware Stockholder Litigation, resulting in an $8.0 million accrued legal settlement liability and a $4.6 million insurance receivable.

Sentiment

Score: 4

Explanation: The company shows strong revenue growth year-over-year for the six-month period and has successfully raised significant capital, which is crucial for its operations. However, the increased net loss, higher cash burn, and a decline in Q2 revenue, partly attributed to NIH budget cuts, indicate ongoing operational challenges and market headwinds. The legal settlement adds a notable expense. The future product pipeline (Proteus) is promising but still in development.

Positives

• Total revenue for the six months ended June 30, 2025, increased by 32.8% to $1.43 million compared to $1.08 million in the prior year.
• Gross profit for the six months ended June 30, 2025, increased by 34.3% to $0.84 million compared to $0.62 million in the prior year.
• Gross profit margin improved to 58.4% for the six months ended June 30, 2025, from 57.7% in the prior year.
• Net loss per common share improved to $(0.26) for the six months ended June 30, 2025, from $(0.30) in the prior year, despite a higher net loss, due to increased shares outstanding.
• Successful completion of a January 2025 Registered Direct Offering, raising $46.8 million in net proceeds.
• Successful completion of a July 2025 Registered Direct Offering (subsequent event), raising an additional $46.9 million in net proceeds.
• Launch of Platinum Pro benchtop sequencer in January 2025, with first shipments in March 2025.
• Development of the next-generation Proteus platform, estimated to launch in the second half of 2026, promising higher sequencing output and automation.
• Management believes current cash, cash equivalents, and marketable securities of $214.2 million are sufficient to fund operations for at least the next twelve months.

Negatives

• Net loss for the six months ended June 30, 2025, increased to $48.0 million from $42.6 million in the prior year.
• Revenue for the three months ended June 30, 2025, decreased by 5.0% to $0.59 million compared to $0.62 million in the same period of 2024.
• Experienced longer capital sales cycles in Q2 2025, largely driven by low or no capital spend budgets at certain customers, primarily due to actual and potential budget cuts from the National Institute of Health (NIH).
• Net cash used in operating activities increased to $46.4 million for the six months ended June 30, 2025, from $41.8 million in the prior year, indicating increased cash burn.
• Accrued a legal settlement liability of $8.0 million related to the Delaware Stockholder Litigation.
• Dividend and interest income decreased by $1.6 million for the six months ended June 30, 2025, due to lower market interest rates and lower average invested capital.
• Ongoing litigation with a former contract manufacturer and a landlord for leasehold improvements, with outcomes not yet estimable or probable.

Risks

• Impact of international conflicts, pandemics, or epidemics on business.
• Impact of general conditions in the global economy and financial markets, including changes in inflation, interest rates, tariffs, and trade policies.
• Ability to maintain the listing of Class A common stock on The Nasdaq Stock Market LLC.
• Changes in applicable laws or regulations.
• Ability to raise future financing on acceptable terms or at all.
• Success, cost, and timing of product development and commercialization activities.
• Commercialization and adoption of existing products (Platinum line, consumable kits) and success of future products.
• Ability to obtain and maintain regulatory approval for products.
• Ability to identify, in-license, or acquire additional technology.
• Ability to maintain existing lease, license, manufacture, and supply agreements.
• Competition from companies with greater financial and marketing resources in proteomic analysis.
• Size and growth potential of markets for products and services, and ability to serve those markets.
• Estimates regarding future expenses, revenue, capital requirements, and needs for additional financing may be inaccurate.
• Inability to generate significant revenue to achieve profitability.
• Constraints in product and material availability and increasing costs due to geopolitical conflicts and global supply chain disruptions.
• Potential adverse impact from increased tariffs on finished goods and/or components.
• Unforeseen capital expenditures and fabrication costs related to manufacturing for commercialization.
• Costs of running a public company.
• Increased product and service costs.
• Uncertainty regarding the outcome and financial exposure of the lawsuit with the former contract manufacturer.
• Uncertainty regarding the outcome and financial impact of the lawsuit against the landlord for lease incentives.
• The preliminary legal settlement for the Delaware Stockholder Litigation is subject to execution of definitive documentation and court approval processes.

Future Outlook

Management believes current cash, cash equivalents, and marketable securities will be sufficient to fund planned operations for at least the next twelve months. The company expects to finance future operations through private and public equity offerings, debt financings, and/or potential future collaboration, license, and development agreements. It anticipates incurring negative operating cash flows annually for the foreseeable future until revenue growth scales. The next-generation Proteus platform is estimated to launch in the second half of 2026, aiming for significantly higher sequencing output and automation.

Management Comments

• We believe that the ability to sequence proteins in a massively parallel fashion and offer a fast analysis time provides NGPS with the potential to unlock significant biological information through improved resolution and unbiased access to the proteome at a speed and scale that is not available today.
• Our evolving product roadmap provides for continued updates and enhancements to our current platform including instrumentation, consumable kits and software tools.
• We intend to execute on this roadmap through a combination of internal development programs and external partnerships to bring to market the most comprehensive proteomics platform in our industry.
• Proteus aims to provide single molecule, amino acid level resolution while also providing significantly higher sequencing output per sample, increased sample throughout per run, automation of the sequencing workflow and automated data analysis.

Industry Context

The company operates in the rapidly evolving proteomics tools market, aiming to differentiate its platform from legacy solutions like mass spectrometry by offering streamlined sequencing, data analysis, lower instrument costs, and greater automation. The focus on Next-Gen Protein Sequencing (NGPS) positions the company to address key challenges in proteomic workflows, such as long completion times and complex data analysis. The reported longer capital sales cycles due to NIH budget cuts indicate a sensitivity to government funding trends within the research sector, a common factor impacting life science tool providers.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. It generally states that its platform aims to address challenges with legacy proteomic solutions like mass spectrometry (MS) by offering lower instrument costs and greater automation, implying a competitive advantage in these areas. However, without specific data points for competitors, a detailed assessment against industry standards is not possible from this filing.

Management Changes

Corporate Governance

Legal Proceedings

• Delaware Stockholder Litigation: A punitive class action lawsuit filed on May 16, 2024, alleging breach of fiduciary duty and unjust enrichment related to the Business Combination. A preliminary settlement was reached on July 22, 2025, resulting in an $8.0 million accrued liability and a $4.6 million insurance receivable, with a net expense of $3.4 million. The settlement is subject to definitive documentation and court approval.
• Former Contract Manufacturer Lawsuit: A complaint filed in October 2023 (refiled January 2024 in Minnesota) alleging breach of contract, economic damage, and attorney costs. The company denied liability and countersued for negligence. A non-binding settlement conference took place in July 2025, with discussions ongoing. The outcome is not estimable or probable.
• New Haven Lease Litigation: A lawsuit filed on September 13, 2022, against the landlord for refusing to reimburse up to $9.1 million in leasehold improvements, delaying completion, and improperly rejecting plans. The company believes it is contractually entitled to the reimbursements, but the outcome and impact on carrying values are not determinable.

Related Party Transactions

• The company incurred immaterial expenses paid to 4Catalyzer Corporation (4C) for the three months ended June 30, 2025, and $0.1 million for the six months ended June 30, 2025, for month-to-month sublease arrangements and administrative expenses.
• Dr. Jonathan Rothberg, Chairman of the Board (now Director), has an Advisory Agreement effective November 1, 2022, for strategic advice and consulting services, for which he was granted an option to purchase 250,000 shares of Class A common stock in March 2023.

Stakeholder Impact

• Shareholders: Dilution from recent equity offerings (January and July 2025) but also significant capital infusion to fund operations. Increased net loss but improved per-share loss due to dilution. Ongoing litigation could impact future financial performance.
• Employees: Organizational restructurings in Q4 2024 aimed to streamline the organization, potentially impacting employee morale or roles. Stock-based compensation remains a significant component of compensation.
• Customers: Launch of Platinum Pro and development of Proteus indicate continued product innovation, potentially benefiting customers with enhanced capabilities. However, longer sales cycles due to NIH budget cuts could affect customer acquisition.
• Creditors: The company's ability to raise significant equity capital reduces immediate reliance on debt, potentially improving creditworthiness.

Next Steps

• Continue systematic, phased approach to launch updates and enhancements to the platform (hardware, software, chemistry).
• Execute on product roadmap through internal development programs and external partnerships.
• Launch of Proteus platform estimated in the second half of 2026.
• Finalize definitive documentation and obtain court approval for the Delaware Stockholder Litigation preliminary settlement.
• Continue ongoing discussions for the non-binding settlement conference regarding the former contract manufacturer lawsuit.
• Continue litigation against the landlord for the New Haven lease improvements.
• Monitor supply chain, inflation, and interest rate factors.
• Assess impact of the One Big Beautiful Bill Act (OBBBA) on Consolidated Financial Statements.

Key Dates

Recommendation

Quantum-Si is in a critical growth phase, marked by significant R&D investment and commercialization efforts for its innovative proteomics platforms. While the company successfully raised substantial capital through recent equity offerings, providing crucial liquidity, it continues to incur significant net losses and cash burn from operations. The decline in Q2 revenue, attributed to NIH budget cuts, highlights market sensitivity. The promising Proteus platform is still in development, and ongoing legal proceedings introduce financial uncertainty. For a seasoned investor, the current financial performance and market headwinds suggest a 'hold' position, awaiting clearer signs of scalable revenue growth, improved operational efficiency, and resolution of legal matters before considering a more aggressive stance.

Keywords

Proteomics, Next-Gen Protein Sequencing, NGPS, Platinum Instrument, Platinum Pro, Proteus Platform, Life Sciences, Biotechnology, Single-Molecule Analysis, Protein Sequencing, Consumables, Diagnostic Tools, Research Instruments, SEC Filing, 10-Q, Capital Raise, Litigation, Financial Results